ITONIS IN |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0006 USD | 0.00% |
|
0.00% | +50.00% |
| 1 month | +50.00% | ||
| 3 months | +20.00% |
More press releases
| Current month | -50.00% | ||
| 1 month | +50.00% | ||
| 3 months | +20.00% | ||
| 6 months | +50.00% | ||
| Current year | +50.00% |
1 week
0.00
0.00
1 month
0.000.00
3 years
0.000.01
5 years
0.000.01
10 years
0.000.02
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Cheung
CEO | Chief Executive Officer | - | 11-05-22 |
Donald Jolly
DFI | Director of Finance/CFO | - | 11-05-22 |
| Corporate Secretary | - | 11-05-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Cheung
CEO | Chief Executive Officer | - | 11-05-22 |
Sam Joudeh
BRD | Director/Board Member | - | - |
Itonis Inc. is a holding company. The Company, through the Itonis Pharmaceuticals division, produces and markets over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Companyâs Emesyl nausea relief product focuses on the general public who suffers from nausea. Emesyl products are available for purchase at https://www.amazon.com and www.Emesyl.com. The Company's subsidiaries include Itonis Holdings, Inc. and Paramount Discoveries, Inc.
| 1st Jan change | Capi. | |
|---|---|---|
| +50.00% | 0 | |
| -2.64% | 33.98B | |
| +1.79% | 31.77B | |
| +6.97% | 5.57B | |
| -0.21% | 3.11B | |
| +13.08% | 2.93B | |
| +20.58% | 2.86B | |
| -21.28% | 2.24B | |
| +4.52% | 1.24B | |
| -3.44% | 1.07B |
- Stock Market
- Equities
- ITNS Stock
